Behavioural Neurology / 2017 / Article / Tab 3

Research Article

Prevalence of Anxiety among Hungarian Subjects with Parkinson’s Disease

Table 3

Comparison of the clinical profile of the Parkinson’s disease patients () with and without anxiety based on the established Parkinson Anxiety Scale threshold value.

No anxiety ()Presence of anxiety ()Statistics
Mean or countSD or percentageMean or countSD or percentage

Age (years)65.89.765.99.9NS
Disease duration (years)
Levodopa dosage (in LED mg)446.7517.6517.3495.0NS
Dopamine agonist usage (in LED mg)175.2212.6149.7229.8NS
Antiparkinson medication (in LED mg)659.5600.4708.0601.2NS
Parkinson Anxiety Scale (total score)6.13.720.26.6
Parkinson Anxiety Scale (Part A)4.32.811.53.2
Parkinson Anxiety Scale (Part B)
Parkinson Anxiety Scale (Part C)
Hamilton Anxiety Scale10.65.717.36.2
Beck Depression Inventory7.75.818.58.8
Montgomery-Asberg Depression Rating Scale8.
Nonmotor Symptoms Scale40.530.076.541.5
Montreal Cognitive Assessment23.
Mattis Dementia Rating Scale135.88.0133.710.4
Lille Apathy Rating Scale−24.18.3−19.810.9
Parkinson’s Disease Questionnaire16.712.232.616.8
MDS-UPDRS ME33.215.438.016.3
MDS-UPDRS total score59.226.878.429.6
Antidepressant usage7219.0%17884.3%
Anxiolytics usage8722.9%16276.7%

LED = levodopa equivalent dosage; MDS-UPDRS = Movement Disorders Society-sponsored version of Unified Parkinson’s Disease Rating Scale; MDS-UPDRS M-EDL = motor experiences of daily living (Part II of MDS-UPDRS); MDS-UPDRS nM-EDL = nonmotor experiences of daily living (Part I of MDS-UPDRS); SD = standard deviation.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.